STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
Anwaar SaeedJosep TaberneroAparna ParikhMarc Van den EyndeMeinolf KarthausMarco GerlingerZhong WangGuan WangRobina SmithJ Randolph HechtPublished in: Future oncology (London, England) (2024)
Most patients with metastatic colorectal cancer (mCRC) have limited treatment options following standard-of-care therapy. VEGFR-tyrosine kinase inhibitors (TKIs) have demonstrated clinical activity in mCRC in combination with immune checkpoint inhibitors (ICIs), particularly in patients without liver metastases. The TKI zanzalintinib (XL092) targets VEGFR, MET and TAM kinases, proteins that are involved in tumor growth, angiogenesis, metastasis and immunosuppression. Zanzalintinib has immunomodulatory properties that may enhance response to ICIs. Presented is the design of STELLAR-303, a global, phase III, open-label, randomized study evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with non-MSI-H mCRC who progressed during/after or are refractory/intolerant to standard-of-care therapy. The primary end point is overall survival in patients without liver metastases. Clinical Trial Registration: NCT05425940 (ClinicalTrials.gov).
Keyphrases
- phase iii
- open label
- clinical trial
- metastatic colorectal cancer
- liver metastases
- phase ii
- double blind
- end stage renal disease
- newly diagnosed
- healthcare
- placebo controlled
- ejection fraction
- chronic kidney disease
- study protocol
- vascular endothelial growth factor
- peritoneal dialysis
- palliative care
- prognostic factors
- randomized controlled trial
- stem cells
- phase ii study
- endothelial cells
- pain management
- radiation therapy
- bone marrow
- chronic pain
- tyrosine kinase
- rectal cancer
- patient reported outcomes
- affordable care act
- wound healing
- advanced non small cell lung cancer
- replacement therapy